Theravance Biopharma Highlights Positive Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort® Turbohaler® Theravance Biopharma Entitled to …